Vectus Biosystems (ASX:VBS) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:VBS Vectus Biosystems Ltd ASX:VBS
15 GF Score
Price A$0.18
! 2 Warning Signs
View Full Analysis

What is Vectus Biosystems FFO?

FFO (Funds from operations) only applies to REITs.

ASX:VBS
15GF Score
Vectus Biosystems Ltd ASX:VBS
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vectus Biosystems Business Description

Address 26-34 Dunning Avenue, Unit 5, Ground Floor, Rosebery, Sydney, NSW, AUS, 2018
Vectus Biosystems Ltd is an emerging biotechnology company based in Sydney, Australia. The company has developed and patented various novel compounds for the treatment of chronic fibrosis, including heart, kidney, liver, and lung fibrosis. Its drug candidate VB0004, is aimed at inhibiting and reversing the loss of functional tissue due to fibrosis, is in its human trials phase.
15GF Score

Get the complete analysis for ASX:VBS

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.18
Price